Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.
Gordy JT, Hui Y, Schill C, Wang T, Chen F, Fessler K, Meza J, Li Y, Taylor AD, Bates RE, Karakousis PC, Pekosz A, Sachithanandham J, Li M, Karanika S, Markham RB. Gordy JT, et al. Among authors: karanika s. Front Immunol. 2024 Feb 2;15:1292059. doi: 10.3389/fimmu.2024.1292059. eCollection 2024. Front Immunol. 2024. PMID: 38370404 Free PMC article.
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.
Ruelas Castillo J, Neupane P, Karanika S, Krug S, Quijada D, Garcia A, Ayeh S, Yilma A, Costa DL, Sher A, Fotouhi N, Serbina N, Karakousis PC. Ruelas Castillo J, et al. Among authors: karanika s. Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0104323. doi: 10.1128/aac.01043-23. Epub 2023 Dec 22. Antimicrob Agents Chemother. 2024. PMID: 38132181
Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.
Fessler K, Gordy JT, Sandhu AK, Hui Y, Kapoor AR, Ayeh SK, Karanika S, Karakousis PC, Markham RB. Fessler K, et al. Among authors: karanika s. Res Sq [Preprint]. 2023 Aug 14:rs.3.rs-3243336. doi: 10.21203/rs.3.rs-3243336/v1. Res Sq. 2023. PMID: 37645859 Free PMC article. Preprint.
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.
Castillo JR, Neupane P, Karanika S, Krug S, Quijada D, Garcia A, Ayeh S, Yilma A, Costa DL, Sher A, Fotouhi N, Serbina N, Karakousis PC. Castillo JR, et al. Among authors: karanika s. bioRxiv [Preprint]. 2023 Nov 13:2023.08.09.552716. doi: 10.1101/2023.08.09.552716. bioRxiv. 2023. PMID: 37609351 Free PMC article. Updated. Preprint.
Human Immunodeficiency Virus and Clonal Hematopoiesis.
Vorri SC, Christodoulou I, Karanika S, Karantanos T. Vorri SC, et al. Among authors: karanika s. Cells. 2023 Feb 22;12(5):686. doi: 10.3390/cells12050686. Cells. 2023. PMID: 36899822 Free PMC article. Review.
IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
Gordy JT, Sandhu AK, Fessler K, Luo K, Kapoor AR, Ayeh SK, Hui Y, Schill C, Chen F, Wang T, Karanika S, Sunshine JC, Karakousis PC, Markham RB. Gordy JT, et al. Among authors: karanika s. Front Immunol. 2023 Jan 19;13:1074644. doi: 10.3389/fimmu.2022.1074644. eCollection 2022. Front Immunol. 2023. PMID: 36741387 Free PMC article.
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis.
Karanika S, Gordy JT, Neupane P, Karantanos T, Ruelas Castillo J, Quijada D, Comstock K, Sandhu AK, Kapoor AR, Hui Y, Ayeh SK, Tasneen R, Krug S, Danchik C, Wang T, Schill C, Markham RB, Karakousis PC. Karanika S, et al. Front Immunol. 2022 Sep 16;13:972266. doi: 10.3389/fimmu.2022.972266. eCollection 2022. Front Immunol. 2022. PMID: 36189260 Free PMC article.
34 results